← Back to Screener
Neumora Therapeutics, Inc. Common Stock (NMRA)
Price$2.19
Favorite Metrics
Price vs S&P 500 (26W)5.01%
Price vs S&P 500 (4W)-23.84%
Market Capitalization$391.39M
All Metrics
Book Value / Share (Quarterly)$0.60
P/TBV (Annual)4.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.18
Price vs S&P 500 (YTD)15.97%
EPS (TTM)$-1.45
10-Day Avg Trading Volume1.21M
EPS Excl Extra (TTM)$-1.45
EPS (Annual)$-1.45
ROI (Annual)-149.57%
Cash / Share (Quarterly)$1.05
ROA (Last FY)-124.02%
EBITD / Share (TTM)$-1.48
ROE (5Y Avg)-90.99%
Cash Flow / Share (Annual)$-1.18
P/B Ratio3.77x
P/B Ratio (Quarterly)2.88x
Net Income / Employee (Annual)$-2
ROA (TTM)-111.57%
EPS Incl Extra (Annual)$-1.45
Current Ratio (Annual)5.87x
Quick Ratio (Quarterly)5.62x
3-Month Avg Trading Volume1.47M
52-Week Price Return241.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.36
52-Week High$3.65
EPS Excl Extra (Annual)$-1.45
26-Week Price Return13.76%
Quick Ratio (Annual)5.62x
13-Week Price Return0.00%
Total Debt / Equity (Annual)0.53x
Current Ratio (Quarterly)5.87x
Enterprise Value$263.39
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.05
3-Month Return Std Dev91.97%
Net Income / Employee (TTM)$-2
ROE (Last FY)-228.10%
EPS Basic Excl Extra (Annual)$-1.45
Total Debt / Equity (Quarterly)0.53x
EPS Incl Extra (TTM)$-1.45
ROI (TTM)-127.93%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.61
Price vs S&P 500 (52W)206.17%
Year-to-Date Return20.11%
5-Day Price Return4.37%
EPS Normalized (Annual)$-1.45
ROA (5Y Avg)-66.89%
Month-to-Date Return10.26%
EBITD / Share (Annual)$-1.48
LT Debt / Equity (Annual)0.53x
ROI (5Y Avg)-75.29%
LT Debt / Equity (Quarterly)0.53x
EPS Basic Excl Extra (TTM)$-1.45
P/TBV (Quarterly)3.53x
P/B Ratio (Annual)2.88x
Book Value / Share (Annual)$0.60
Price vs S&P 500 (13W)-2.87%
Beta2.93x
Revenue / Share (TTM)$0.00
ROE (TTM)-146.42%
52-Week Low$0.61
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.86
3.93
4.07
4.07
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NMRANeumora Therapeutics, Inc. Common Stock | — | — | — | — | $2.19 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 11.09x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for neuropsychiatric and neurodegenerative diseases. Its pipeline consists of seven clinical and preclinical programs targeting new mechanisms of action in underserved areas of neuroscience. The company aims to address significant unmet medical needs through its differentiated approach to brain disease treatment.